Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Evidence supports routine supplementation for elderly people and others at risk
Vitamin D is both a vitamin and a hormone and has
diverse actions. The major biologically active metabolite,
1,25-dihydroxyvitamin D, plays a central part in maintaining calcium
and phosphate homoeostasis and also has antiproliferative,
prodifferentiation, and immunosuppressive effects; its receptors are
distributed in various tissues, including bone, pancreas, stomach,
gonads, brain, skin, and breast.1 Vitamin D is essential
for skeletal health, and severe deficiency is associated with defective
mineralisation resulting in rickets or its adult equivalent,
osteomalacia. More subtle degrees of insufficiency lead to secondary
hyperparathyroidism and increased bone turnover, which play an
important part in age related bone loss and osteoporotic fractures.
Over recent decades a wealth of evidence has accumulated documenting
vitamin D deficiency in elderly populations in Europe and
elsewhere.
2 3
A recent study from the United States has added further evidence that vitamin D deficiency continues to be
neglected and also raised questions about how best to combat it.4
Vitamin D status is most commonly assessed by measuring serum
concentrations of 25-hydroxyvitamin D (25-OHD), the major
circulating form of the hormone. These show marked seasonal variation,
reflecting the importance in healthy subjects of cutaneous synthesis as
a source of the vitamin. Natural dietary sources of vitamin D are limited, and their contribution to vitamin D status assumes importance only in individuals with reduced exposure to sunlight. Serum 25-OHD concentrations below 20 nmol/l are generally regarded as indicating severe vitamin D deficiency, but circulating concentrations up to
37.5 nmol/l may be associated with adverse skeletal
effects,5 and even higher levels may be required for
optimal skeletal health, particularly in elderly people.
Other populations at risk include housebound and institutionalised
people; those who avoid exposure to sunlight for cultural reasons or
because of skin disease; patients with intestinal, liver, renal, or
cardiopulmonary disease; and those taking anticonvulsants. In their
recent study of 290 patients on a general medical ward at Massachusetts
General Hospital Thomas et al found that 57% had serum 25-OHD
concentrations at or below 37.5 nmol/l and 22% of these had values
below 20 nmol/l.4 Not surprisingly, low vitamin D intake,
housebound status, and winter season were independent predictors of
hypovitaminosis D. However, vitamin D deficiency was also seen in
patients with vitamin D intakes above recommended levels and in some
cases occurred in the absence of known risk factors.
This study thus suggests that the currently recommended intakes of
vitamin D are inadequate; in the United States these are 400 IU (10 µg) daily for those aged 51-70 years and 600 IU (15 µg) daily for
those aged 71 and over, while in the United Kingdom 400 IU (10 µg)
daily is recommended for people aged 65 years or over. Correction of
privational vitamin D deficiency is safe, effective, and cheap. There
is thus a powerful case for preventive strategies, particularly in high
risk populations, and there are several ways in which these might be
implemented.
The limited natural supply of vitamin D in food makes any increase in
the recommended intake unlikely to be successful unless foods are more
widely fortified. Even then fortification may not be effective in
people with restricted dietary intakes, and amounts of vitamin D
present in fortified foods can be variable.6 Exposure to
ultraviolet irradiation is effective in correcting vitamin D deficiency
and secondary hyperparathyroidism in elderly people,7 but
concerns about skin cancer make this practice unlikely to be widely
adopted. The most rational approach to reducing vitamin D deficiency is
supplementation; uncertainty exists, however, about the best dose and
route of administration and whether calcium supplements are also
necessary.
Two randomised controlled trials of oral vitamin D (800 (20 µg) and
700 (17.5 µg) IU/day respectively) and calcium supplements in elderly
subjects showed significant reductions in the rate of non-vertebral
fractures
8 9
and one also showed a significant reduction
in the incidence of hip fracture.8 However, the relative contribution of vitamin D and calcium to these benefits is unknown. In
contrast, administration of 400 IU (10 µg) daily of vitamin D to
elderly subjects with a high calcium intake produced no reduction in
fracture rate.10 An open, quasirandomised study of annual injections of 150 000-300 000 IU of vitamin D showed a significant reduction in overall fracture rate but not in the rate of hip fractures
in treated subjects.11 The key issue of whether vitamin D
supplementation alone is effective in preventing hip fractures thus
remains unresolved; this has important implications both for compliance
and cost, since calcium supplements are not always well tolerated and
add substantially to the costs of intervention.12
As the study by Thomas et al shows, hypovitaminosis D remains a common
and neglected problem4 despite numerous reports of its
high prevalence in susceptible populations and recognised adverse
effects on bone mass and fracture risk. Resolving the current
uncertainties about the optimal method of supplementation is an
important research priority. In the meantime, the rationale for routine
vitamin D supplementation in elderly and other high risk populations is
compelling. The available evidence suggests that 800 IU (20 µg) daily
should be advised; this dose is safe, free of side effects, and should
have an impact on the enormous and increasing morbidity and cost
attributable to osteoporotic fractures in elderly people.
Department of Medicine, Addenbrooke's Hospital, Cambridge
CB2 2QQ
© BMJ 1998
Read all Rapid Responses
What can you learn from this BMJ paper? Read Leanne Tite's Paper+